Quick Answer
C4 Therapeutics, Inc. reported R&D Expense of $104.24 million for fiscal year 2025.
C4 Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $104.24M | -5.8% |
| 2024 | $110.64M | -6.0% |
| 2023 | $117.71M | -0.1% |
| 2022 | $117.84M | +24.5% |
| 2021 | $94.67M | +20.7% |
| 2020 | $78.44M | +63.2% |
| 2019 | $48.06M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.99M | -18.4% | -0.8% |
| June 30, 2025 | $26.20M | +10.3% | -3.2% |
| March 31, 2025 | $27.07M | +20.1% | -15.0% |
| September 30, 2024 | $31.84M | +12.3% | +34.0% |
| June 30, 2024 | $23.75M | -20.6% | +5.4% |
| March 31, 2024 | $22.53M | -22.4% | -20.5% |
| September 30, 2023 | $28.35M | -4.4% | -5.3% |
| June 30, 2023 | $29.93M | -4.5% | +3.0% |
- C4 Therapeutics, Inc. showed a decrease of -5.8% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, C4 Therapeutics, Inc.’s r&d expense has grown by 116.9% (from $48.06 million to $104.24 million).
- The most recent figure is from C4 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: